Physician profile
Daniela M Burchhardt
NPI 1205196961
$827.84
in general payments reported to CMS, 2019-2025
14 companies · $173 in 2025
The $173 reported for 2025 was less than what a typical Facial Plastic Surgery provider received nationally (typical 2025 total: $271).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $46.21 · 2020: $45.16 · 2021: $17.63 · 2022: $186 · 2023: $239 · 2024: $120 · 2025: $173.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $533.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $532.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $305.58 | 2023-2025 | Xeomin |
| Galderma Laboratories, L.P. | $205.16 | 2019-2022 | |
| Incyte Corporation | $48.69 | 2023-2024 | Opzelura |
| Musculoskeletal Transplant Foundation INC. | $45.16 | 2020 | |
| Abbvie INC. | $33.45 | 2025 | |
| Lilly USA, LLC | $29.01 | 2024 | Olumiant, Taltz |
| Smith+Nephew, INC. | $24.75 | 2022 | |
| Kyowa Kirin, INC. | $20.71 | 2023 | Poteligeo |
| Glaxosmithkline, LLC. | $20.06 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.97 | 2023 | Spevigo |
| Revance Therapeutics, INC. | $19.86 | 2024 | Daxxify |
| Organogenesis INC. | $18.72 | 2024 | |
| Novartis Pharmaceuticals Corporation | $18.58 | 2025 | |
| Janssen Biotech, INC. | $18.14 | 2023 | Simponi Aria, Simponi, Remicade |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniela Burchhardt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.